In a phase 3b trial comparing treatments for iron-deficiency anemia in inflammatory bowel disease, ferric maltol demonstrated clinical effectiveness but fell short of showing noninferiority to intravenous ferric carboxymaltose at week 12.
In a phase 3b trial comparing treatments for iron-deficiency anemia in inflammatory bowel disease, ferric maltol demonstrated clinical effectiveness but fell short of showing noninferiority to intravenous ferric carboxymaltose at week 12.
